(BQ) Part 1 book “Brant and helms’ fundamentals of diagnostic radiology” has contents: Diagnostic imaging methods, introduction to brain imaging, craniofacial trauma, cerebrovascular disease, central nervous system infections, spine imaging, pulmonary vascular disease,… and other contents.
SECTION EDITORS SECTION I BASIC PRINCIPLES William E Brant, MD, FACR Professor Emeritus Department of Radiology and Medical Imaging University of Virginia School of Medicine Charlottesville, Virginia SECTION II NEURORADIOLOGY Erik H L Gaensler, MD Clinical Professor Department of Radiology and Biomedical Imaging University of California, San Francisco Neuroradiologist Bay Imaging Consultants Jerome A Barakos, MD Director of Neuroimaging Department of Radiology California Pacific Medical Center San Francisco, California SECTION III CHEST Jeffrey S Klein, MD, FACR A Bradley Soule and John P Tampas Green and Gold Professor of Radiology Department of Radiology Larner College of Medicine at the University of Vermont Burlington, Vermont SECTION IV BREAST RADIOLOGY Brandi T Nicholson, MD, FSBI Associate Professor Department of Radiology and Medical Imaging University of Virginia School of Medicine Charlottesville, Virginia SECTION V CARDIAC RADIOLOGY Seth Kligerman, MD Associate Professor Division Chief of Cardiothoracic Radiology Department of Radiology University of California, San Diego San Diego, California SECTION VI VASCULAR AND INTERVENTIONAL RADIOLOGY Juan C Camacho, MD Assistant Attending Radiologist Interventional Radiology Memorial Sloan Kettering Cancer Center Assistant Professor Department of Radiology Weill Cornell Medical College New York, New York Akhilesh K Sista, MD, FSIR Associate Professor and Section Chief Vascular Interventional Radiology Department of Radiology New York University School of Medicine New York, New York SECTION VII GASTROINTESTINAL TRACT William E Brant, MD, FACR Professor Emeritus Department of Radiology and Medical Imaging University of Virginia School of Medicine Charlottesville, Virginia SECTION VIII GENITOURINARY TRACT William E Brant, MD, FACR Professor Emeritus Department of Radiology and Medical Imaging University of Virginia School of Medicine Charlottesville, Virginia involved percutaneous ethanol injection, termed ethanol ablation, which has been shown to safely achieve complete necrosis of small HCCs and has the advantage of allowing treatment of tumors near sensitive organs and blood vessels However, it typically requires multiple treatment sessions, one cannot be certain of the ablation zone, and there are high local progression and recurrence rates (Fig 39.23) FIGURE 39.22 Radiation lobectomy A: Celiac angiogram demonstrating a large mass within segment VII and VIII of the liver with corresponding tumor blush (arrows) B: SPECT-CT 90Y bremsstrahlung axial image confirming complete tumoral distribution by the therapy as well as counts within the normal liver C: Preprocedural contrast-enhanced CT at the level of the portal vein demonstrating a small left lateral segment which will become the future liver remnant D: Axial T1W postcontrast image demonstrating delayed enhancement of the right lobe corresponding to postprocedural fibrosis along with significant hypertrophy of the left lateral segment E: Intraoperative view of the liver corroborating significant hypertrophy of the left lateral segment and fibrosis of the treated right lobe (arrow) Acetic Acid Ablation Percutaneous acetic acid injection for ablation of tumors was first described in 1994 Acetic acid is a noxious chemical with better tissue diffusion than ethanol as well as better infiltration into tumor septae and capsules, proposed to decrease the number of repeat ablation sessions It is generally considered safe, with rare side effects including transient hemoglobinuria, fever, and right upper quadrant abdominal pain Segmental infarction and metabolic acidosis can occur at high doses TABLE 39.3 COMPARISON OF AVAILABLE SIRT PARTICLES TABLE 39.4 ADVANTAGES AND DISADVANTAGES OF EACH ABLATION METHOD Energy-Based Ablation Radiofrequency Ablation Radiofrequency ablation (RFA) utilizes a probe generating electromagnetic radiation within the radiofrequency spectrum, part of the electromagnetic spectrum bound by a low oscillation of Hz and a high of 300 GHz, with most RFA probes generating electromagnetic radiation in the 300 to 500 kHz range The probe is inserted within the target lesion, typically using CT or ultrasound guidance, and the circuit is closed by placing grounding pads on the patient’s body, usually the thighs A generator modulates the radiofrequency amplitude, and the resultant energy is locally deposited in the form of heat as a result of molecular frictional loss, resulting in coagulative tissue necrosis Effective ablation requires good tissue conductivity, which allows heat transfer farther away from the probe and a larger ablation zone Counterintuitively, a fast power increase will result in desiccation of the tissue around the probe, limiting heat conduction and decreasing the size of the ablation zone The eventual ablation zone geometry depends on multiple factors including the type and shape of the probe, maximum temperature reached, duration of ablation, and proximity to blood vessels Lesion size is the most important determinant of RFA success, with reported complete ablation rates of about 90% for lesions up to cm For lesions >3 cm, the efficacy of RFA decreases with increasing lesion size Complete ablation is possible for lesions of to cm but unlikely with lesions >5 cm The rate of recurrence is nearly 0% for smaller lesions and >50% for lesions >5 cm Lesion location is also a determinant of RFA success RFA of lesions near the hilum is generally avoided due to the risk of injury to the central biliary tree or hepatic vasculature Additionally, lesions adjacent to blood vessels may show variable ablation response secondary to the heatsink effect, whereby generated heat is dissipated by the adjacent flowing flood FIGURE 39.23 Percutaneous ethanol ablation A: Axial T1W postcontrast image in the hepatobiliary phase demonstrating a lesion within the posterior aspect of segment III (arrow), in close proximity to the stomach, the portal vein and adjacent bile ducts, in a patient that underwent right hepatectomy due to metastatic colorectal cancer B: CT image demonstrating needle placement within the lesion C: Subsequent ethanol injection was performed, which was confirmed by noncontract CT (arrow) D: Axial T1W postprocedural image demonstrating absence of enhancement of the ablation cavity, compatible with lesion necrosis (arrow) RFA may offer the same benefit as resection in selected patients Child– Pugh class A or B patients with lesions up to cm treated with RFA demonstrate similar overall survival rates to those treated with surgical resection Although Child–Pugh class C patients may be safely treated with RFA, their life expectancy is determined by the progression of cirrhosis and a survival benefit is therefore unlikely Liver transplantation for HCC offers the longest survival for the approximately 10% of patients who are candidates, and treatment with RFA while awaiting liver transplantation has been shown to be an independent prognostic factor for longer survival Deaths after RFA are uncommon and typically attributed to liver failure, and risk increases with larger ablation volumes and diminished hepatic reserve Most patients treated with RFA for HCC may be discharged home on the day of the procedure after several hours of observation Microwave Ablation Microwave ablation (MWA) refers to all electromagnetic methods of inducing tumor destruction via coagulative tissue necrosis by using devices with frequencies greater than or equal to 900 MHz MWA uses an oscillating electromagnetic field that realigns polarized molecules such as water, generating kinetic energy, heat, and subsequent tumor necrosis through dielectric hysteresis This creates an ablation zone around the needle in a column or rounded shape, depending on the type of needle used and the generating power Compared to RFA, MWA shows more uniform tissue penetration, does not require grounding pads, is less prone to heat-sink effect, is not affected by tissue carbonization, and has a more predictable ablation zone (Fig 39.24) Cryoablation Most cryoablation systems rely on the Joule–Thomson effect, whereby expansion of a cryogen (i.e., argon) at the cryoprobe tip causes the temperature to decrease Cell death induced by cryoablation is caused by direct intracellular ice crystal formation resulting in damage to plasma membranes and organelles The ice crystals continue to grow during thawing, maximizing cell killing Tumor response depends on the rate of cooling, depth of hypothermia, rate of thawing, the number of freeze–thaw cycles, and delayed effects of postthaw ischemia Repeated freeze–thaw cycles can improve the efficacy The large diameter of currently available probes, the requirement of using multiple probes, the location of many tumors, and the risk of cryoshock syndrome, a clinical syndrome caused by circulating inflammatory cytokines and characterized by renal failure, disseminated intravascular coagulation, and adult respiratory distress syndrome, significantly limit its application in the liver Irreversible Electroporation Irreversible electroporation (IRE) uses pulsed electric fields to induce cell death At a specific electric potential threshold, the cell membrane lipid bilayer becomes inundated with pores, a change that is reversible at low current but which becomes permanent and results in cell death as the electric field strength is increased Ablation of liver lesions using IRE was first described in 2005 by Davalos et al IRE devices can deliver up to 3,000 V and 50 A through either unipolar or bipolar needle electrodes Ablation zone size can be influenced by length of the electrode tip, distance between electrodes, pulse number, duration of pulses, and voltage applied Electric fields are strongly influenced by the conductivity of the local environment, which depends on tissue heterogeneity and the presence of metal such as biliary stents Since IRE does not depend on heating or cooling of target tissues, the technique is not limited by the heat-sink effect when performing ablation of tumors close to major blood vessels and does not appear to have deleterious effects on adjacent normal tissues including nerves and bile ducts However, despite these advantages over thermal ablative techniques, multiple groups have suggested poor local control and high recurrence rates with IRE Therefore, IRE should only be considered when thermal ablative techniques are contraindicated FIGURE 39.24 Percutaneous microwave ablation A: Contrast-enhanced CT image demonstrating a lesion within the posterior right lobe (arrow) B: Noncontrast CT image demonstrating the exophytic lesion during the actual procedure (arrow) C: Subsequently, a microwave antennae was advanced into the lesion under direct ultrasound guidance D: Immediate postprocedural ultrasound demonstrating expected postprocedural changes (arrow) with (E) the expected perilesional halo on noncontrast CT (arrow), indicating technical success and tissue retraction FIGURE 39.25 Scheme demonstrating the available follow-up criteria and their specific therapeutic targets Laser Ablation Laser ablation uses a laser to generate monochromatic light and a small flexible optical fiber to transport the light inside tissue where it is then converted to heat Tumor cell exposure to temperatures ranging from 45° to 55°C for prolonged periods or temperatures higher than 60°C for short periods causes irreversible cell damage Heat generation in the target tissue is influenced by multiple factors including laser light wavelength, laser power, laser energy, treatment time, the emission characteristics of the optical fiber, and characteristics of the tissue Various invasive and noninvasive methods are available for real-time temperature monitoring with good spatial resolution, facilitating tumor killing with sparing of as much normal tissue as possible Additionally, nanoparticles are being developed for use in photothermal tumor ablation that highly absorb light and can be designed and delivered specifically to tumor cells FIGURE 39.26 Scheme demonstrating the available anatomic criteria and their basic measuring strategies PRINCIPLES OF ASSESSING TREATMENT RESPONSE Assessment of tumor response is crucial in patients undergoing locoregional liver cancer therapies Conventional methods, such as classical Response Evaluation Criteria in Solid Tumors (RECIST) criteria, have no predictive value in HCC patients treated with TACE or SIRT as they rely solely on tumor shrinkage as a measure of antitumor activity, an assumption that is only valid with cytotoxic drugs TACE and SIRT induce direct tumor necrosis and their anticancer activity is predictive to a reduction in viable tumor, as identified by contrast-enhanced CT or MRI The Clinical Practice Guidelines jointly issued by the European Association for the Study of Liver Disease (EASL) and the European Organization for Research and Treatment of Cancer (EORTC) therefore state that assessment of response in HCC should be based on modified RECIST (mRECIST) criteria by performing contrast-enhanced CT or MRI weeks after treatment to assess residual viable tumor burden as well as for vascular invasion, lymph nodes, ascites, pleural effusion, and new lesions Tumor response measured by mRECIST after TACE has been shown to correlate with survival outcomes (Figs 39.25 and 39.26) If complete tumor necrosis is not achieved after the first TACE, a second TACE may be performed as some feeding arteries may have been missed However, patients that not respond to two consecutive sessions of TACE should be considered for alternative therapies, and those that show no tumor response following TACE have a worse prognosis All response criteria that measure the tumor dimensionally (RECIST and mRECIST), presume that lesion diameter directly correlates with lesion volume This assumption is based on the belief that tumors grow and shrink in a spherical manner, which is not entirely accurate Therefore, quantification by volumetry can be a more accurate reflection of the actual tumor size and additional methods have been developed in order to quantify such a change Also, quantitative imaging techniques allow robust evaluation of hepatic tumor response In addition to size changes, various biologic and functional parameters such as diffusion and perfusion can be quantified Measurement of these parameters is especially important for the evaluation of tumor response to novel targeted therapies including SIRT, in which a change in functional status sometimes precedes anatomic modification Other biomarkers have been explored including AFP Preprocedural AFP has not been demonstrated to be a prognostic marker of clinical response following intervention AFP elevation may be seen in the immediate postprocedure period secondary to cellular lysis rather than disease progression, and while decrease in AFP following treatment is indicative of response, it is unreliable and AFP monitoring should not be substituted in place of dynamic imaging studies CONCLUSION Management of hepatic malignancies requires a multidisciplinary approach and the ability to translate basic anatomical and radiologic concepts into daily clinical practice Decisions are often based on the tumor burden, liver function, imaging findings, and patient presentation, including a judicious evaluation of patient performance status Locoregional therapies offer multiple options with different treatment objectives Currently, ablation therapies including SIRT segmentectomy can be used in a potentially curative manner The remaining therapies are typically used in a palliative or downstaging setting Each of the available locoregional treatments offers specific advantages and must be individualized to each patient in order to achieve the desired optimal outcome Suggested Readings Arch-Ferrer JE, Smith JK, Bynon S, et al Radio-frequency ablation in cirrhotic patients with hepatocellular carcinoma Am Surg 2003;69(12):1067–1071 Basile A, Tsetis D, Montineri A, et al MDCT anatomic assessment of right inferior phrenic artery origin related to potential supply to hepatocellular carcinoma and its embolization Cardiovasc Intervent Radiol 2008;31(2):349–358 Bismuth H Surgical anatomy and anatomical surgery of the liver World J Surg 1982;6(1):3–9 Brown KT, Do RK, Gonen M, et al Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone J Clin Oncol 2016;34(17):2046–2053 Brown KT, Nevins AB, Getrajdman GI, et al Particle embolization for hepatocellular carcinoma J Vasc Interv Radiol 1998;9(5):822–828 Camma C, Di Marco V, Orlando A, et al; Unità Interdipartimentale Neoplasie Epatiche (U.I.N.E) Group Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study J Hepatol 2005;42(4):535–540 Camma C, Schepis F, Orlando A, et al Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials Radiology 2002;224(1):47–54 Cannon R, Ellis F, Hayes D, Narayanan G, Martin RC 2nd Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures J Surg Oncol 2013;107(5):544–549 Carr BI Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients Liver Transpl 2004;10(2 Suppl 1):S107– S110 Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE Irreversible electroporation of the liver and liver hilum in swine HPB (Oxford) 2011;13(3):168–173 Chung JW, Kim HC, Yoon JH, et al Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients Korean J Radiol 2006;7(4):257–266 Clark TW Complications of hepatic chemoembolization Semin Intervent Radiol 2006;23(2):119–125 Coster HG A quantitative analysis of the voltage-current relationships of fixed charge membranes and the associated property of “punch-through” Biophys J 1965;5(5):669–686 Couinaud C Le foie: études anatomiques et chirurgicales Masson & Cie; 1957 Covey AM, Brody LA, Maluccio MA, Getrajdman GI, Brown KT Variant hepatic arterial anatomy revisited: digital subtraction angiogram performed in 600 patients Radiology 2002;224(2):542–547 Crucitti A, Danza FM, Antinori A, et al Radiofrequency thermal ablation (RFA) of liver tumors: percutaneous and open surgical approaches J Exp Clin Cancer Res 2003;22(4 Suppl):191–195 Davalos RV, Mir IL, Rubinsky B Tissue ablation with irreversible electroporation Ann Biomed Eng 2005;33(2):223–231 Doyon D, Mouzon A, Jourde AM, Regensberg C, Frileux C [Hepatic, arterial embolization in patients with malignant liver tumours (author’s transl)] Ann Radiol (Paris) 1974;17(6):593–603 Dumortier J, Chapuis F, Borson O, et al Unresectable hepatocellular carcinoma: survival and prognostic factors after lipiodol chemoembolisation in 89 patients Dig Liver Dis 2006;38(2):125–133 Forner A, Ayuso C, Varela M, et al Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009;115(3):616–623 Furuta T, Maeda E, Akai H, et al Hepatic segments and vasculature: projecting CT anatomy onto angiograms Radiographics 2009;29(7):e37 Georgiades CS, Hong K, Geschwind JF Radiofrequency ablation and chemoembolization for hepatocellular carcinoma Cancer J 2008;14(2):117–122 Gillmore R, Stuart S, Kirkwood A, et al EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization J Hepatol 2011;55(6):1309–1316 Goldsmith NA, Woodburne RT The surgical anatomy pertaining to liver resection Surg Gynecol Obstet 1957;105(3):310–318 Goseki N, Nosaka T, Endo M, Koike M Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization Cancer 1995;76(5):736–742 Gruttadauria S, Foglieni CS, Doria C, Luca A, Lauro A, Marino IR The hepatic artery in liver transplantation and surgery: vascular anomalies in 701 cases Clin Transplant 2001;15(5):359–363 Guglielmi A, Ruzzenente A, Sandri M, et al Radio frequency ablation for hepatocellular carcinoma in cirrhotic patients: prognostic factors for survival J Gastrointest Surg 2007;11(2):143–149 Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio J Transl Med 2007;5:15 Hasegawa S, Yamasaki N, Hiwaki T, et al Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection Cancer 1999;86(9):1682– 1690 Healey JE Jr, Schroy PC Anatomy of the biliary ducts within the human liver; analysis of the prevailing pattern of branchings and the major variations of the biliary ducts AMA Arch Surg 1953;66(5):599– 616 Hiatt JR, Gabbay J, Busuttil RW Surgical anatomy of the hepatic arteries in 1000 cases Ann Surg 1994;220(1):50–52 Hjortsjo CH The topography of the intrahepatic duct systems Acta Anat (Basel) 1951;11(4):599–615 Huo TI, Huang YH, Wu JC, et al Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study Ann Oncol 2003;14(11):1648–1653 Idee JM, Guiu B Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review Crit Rev Oncol Hematol 2013;88(3):530–549 Izzo F Other thermal ablation techniques: microwave and interstitial laser ablation of liver tumors Ann Surg Oncol 2003;10(5):491–497 Kadir S, Brothers MF Atlas of Normal and Variant Angiographic Anatomy 1st ed 1991, Philadelphia, PA: Saunders xi, 529 pp Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers Int J Radiat Oncol Biol Phys 2004;60(5):1552–1563 Kim HC, Chung JW, Lee W, Jae HJ, Park JH Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization Radiographics 2005;25 Suppl 1:S25–S39 Kim W, Clark TW, Baum RA, Soulen MC Risk factors for liver abscess formation after hepatic chemoembolization J Vasc Interv Radiol 2001;12(8):965–968 Kim BK, Kim KA, An C, et al Prognostic role of magnetic resonance imaging vs computed tomography for hepatocellular carcinoma undergoing chemoembolization Liver Int 2015;35(6):1722–1730 Kim HC, Kim TK, Sung KB, et al CT during hepatic arteriography and portography: an illustrative review Radiographics 2002;22(5):1041–1051 Kingham TP, Karkar AM, D’Angelica MI, et al Ablation of perivascular hepatic malignant tumors with irreversible electroporation J Am Coll Surg 2012;215(3):379–387 Knesaurek K, Machac J, Muzinic M, DaCosta M, Zhang Z, Heiba S Quantitative comparison of yttrium-90 (90Y)-microspheres and technetium-99m (99mTc)-macroaggregated albumin SPECT images for planning 90Y therapy of liver cancer Technol Cancer Res Treat 2010;9(3):253–262 Koda M, Murawaki Y, Mitsuda A, et al Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma Cancer 2000;88(3):529–537 Konno T, Maeda H, Iwai K, et al Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report Eur J Cancer Clin Oncol 1983;19(8):1053–1065 Kusano S, Matsubayashi T, Ishii K [The evaluation of the angiographic “umbilical point” of the left hepatic artery (author’s transl)] Nihon Igaku Hoshasen Gakkai Zasshi 1976;36(1):7–12 Lau WY, Leung TW, Ho S, et al Diagnostic pharmaco-scintigraphy with hepatic intra-arterial technetium99m macroaggregated albumin in the determination of tumour to non-tumour uptake ratio in hepatocellular carcinoma Br J Radiol 1994;67(794):136–139 Lee AJ, Gomes AS, Liu DM, Kee ST, Loh CT, McWilliams JP The road less traveled: importance of the lesser branches of the celiac axis in liver embolotherapy Radiographics 2012;32(4):1121–1132 Lencioni R, Bartolozzi C, Caramella D, et al Treatment of small hepatocellular carcinoma with percutaneous ethanol injection Analysis of prognostic factors in 105 Western patients Cancer 1995;76(10):1737– 1746 Lencioni R, Llovet JM Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 2010;30(1):52–60 Lewis AL, Gonzalez MV, Lloyd AW, et al DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization J Vasc Interv Radiol 2006;17(2 Pt 1):335–342 Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization J Vasc Interv Radiol 2006;17(8):1335–1343 Liapi E, Geschwind JF, Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol 2011;34(1):37–49 Liu DM, Salem R, Bui JT, et al., Angiographic considerations in patients undergoing liver-directed therapy J Vasc Interv Radiol 2005;16(7):911–935 Livraghi T, Giorgio A, Marin G, et al Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection Radiology 1995;197(1):101–108 Livraghi T, Goldberg SN, Lazzaroni S, et al Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions Radiology 2000;214(3):761–768 Llovet JM Updated treatment approach to hepatocellular carcinoma J Gastroenterol 2005;40(3):225–235 Loffroy R, Estivalet L, Favelier S, et al Interventional radiology therapies for liver cancer Hepatoma Research 2016;2(1):1–9 Lu MD, Chen JW, Xie XY, et al Hepatocellular carcinoma: US-guided percutaneous microwave coagulation therapy Radiology 2001;221(1):167–172 Lu DS, Siripongsakun S, Kyong Lee J, et al., Complete tumor encapsulation on magnetic resonance imaging: a potentially useful imaging biomarker for better survival in solitary large hepatocellular carcinoma Liver Transpl 2013;19(3):283–291 Ludwig JM, Camacho JC, Kokabi N, Xing M, Kim HS The role of diffusion-weighted imaging (DWI) in locoregional therapy outcome prediction and response assessment for hepatocellular carcinoma (HCC): the new era of functional imaging biomarkers Diagnostics (Basel) 2015;5(4):546–563 Lunderquist A Arterial segmental supply of the liver An angiographic study Acta Radiol Diagn (Stockh) 1967:Suppl 272:1+ Mantatzis M, Kakolyris S, Amarantidis K, Karayiannakis A, Prassopoulos P Treatment response classification of liver metastatic disease evaluated on imaging Are RECIST unidimensional measurements accurate? Eur Radiol 2009;19(7):1809–1816 Matsui O, Kadoya M, Kameyama T, et al Benign and malignant nodules in cirrhotic livers: distinction based on blood supply Radiology 1991;178(2):493-497 McWilliams JP, Kee ST, Loh CT, Lee EW, Liu DM Prophylactic embolization of the cystic artery before radioembolization: feasibility, safety, and outcomes Cardiovasc Intervent Radiol 2011;34(4):786–792 Michels NA Variational anatomy of the hepatic, cystic, and retroduodenal arteries; a statistical analysis of their origin, distribution, and relations to the biliary ducts in two hundred bodies AMA Arch Surg 1953;66(1):20–34 Miyayama S, Matsui O Superselective conventional transarterial chemoembolization for hepatocellular carcinoma: rationale, technique, and outcome J Vasc Interv Radiol 2016;27(9):1269–1278 Miyayama S, Matsui O, Kameyama T, et al [Angiographic anatomy of arterial branches to the caudate lobe of the liver with special reference to its effect on transarterial embolization of hepatocellular carcinoma] Rinsho Hoshasen 1990;35(3):353–359 Mondazzi L, Bottelli R, Brambilla G, et al Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors Hepatology 1994;19(5):1115– 1123 Murphy KP, Maher MM, O’Connor OJ Abdominal ablation techniques AJR Am J Roentgenol 2015;204(5):W495–W502 Ohnishi K Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma Hepatogastroenterology 1998;45 Suppl 3:1254–1258 Ohnishi K, Ohyama N, Ito S, Fujiwara K Small hepatocellular carcinoma: treatment with US-guided intratumoral injection of acetic acid Radiology 1994;193(3):747–752 Riaz A, Gates VL, Atassi B, et al Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization Int J Radiat Oncol Biol Phys 2011;79(1):163–171 Ruzicka FF Jr, Rossi P Normal vascular anatomy of the abdominal viscera Radiol Clin North Am 1970;8(1):3–29 Salem R, Mazzaferro V, Sangro B Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives Hepatology 2013;58(6):2188-2197 Sancho L, Rodriguez-Fraile M, Bilbao JI, et al Is a technetium-99m macroaggregated albumin scan essential in the workup for selective internal radiation therapy with yttrium-90? An analysis of 532 patients J Vasc Interv Radiol 2017;28(11):1536–1542 Sangro B Chemoembolization and radioembolization Best Pract Res Clin Gastroenterol 2014;28(5):909919 Sangro B, Carpanese L, Cianni R, et al; European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY) Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation Hepatology 2011;54(3):868–878 Sangro B, D’Avola D, Iñarrairaegui M, Prieto J Transarterial therapies for hepatocellular carcinoma Expert Opin Pharmacother 2011;12(7):1057–1073 Sangro B, Gil-Alzugaray B, Rodriguez J, et al Liver disease induced by radioembolization of liver tumors: description and possible risk factors Cancer 2008;112(7):1538–1546 Sangro B, Inarrairaegui M, Bilbao JI Radioembolization for hepatocellular carcinoma J Hepatol 2012;56(2):464-473 Schena E, Saccomandi P, Fong Y Laser ablation for cancer: past, present and future J Funct Biomater 2017;8(2):E19 Schoellnast H, Monette S, Ezell PC, et al Acute and subacute effects of irreversible electroporation on nerves: experimental study in a pig model Radiology 2011;260(2):421–427 Seidenfeld J, Korn A, Aronson N Radiofrequency ablation of unresectable primary liver cancer J Am Coll Surg 2002;194(6):813–828; discussion 828 Shiina S, Tagawa K, Niwa Y, et al Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients AJR Am J Roentgenol 1993;160(5):1023–1028 Shim JH, Lee HC, Kim SO, et al Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models Radiology 2012;262(2):708–718 Silk M, Tahour D, Srimathveeravalli G, Solomon SB, Thornton RH The state of irreversible electroporation in interventional oncology Semin Intervent Radiol 2014;31(2):111–117 Silk MT, Wimmer T, Lee KS, et al Percutaneous ablation of peribiliary tumors with irreversible electroporation J Vasc Interv Radiol 2014;25(1):112–118 Song SY, Chung JW, Kwon JW, et al Collateral pathways in patients with celiac axis stenosis: angiographicspiral CT correlation Radiographics 2002;22(4):881–893 Stafford RJ, Fuentes D, Elliott AA, Weinberg JS, Ahrar K Laser-induced thermal therapy for tumor ablation Crit Rev Biomed Eng 2010;38(1):79–100 Stroehl YW, Letzen BS, van Breugel JM, Geschwind JF, Chapiro J Intra-arterial therapies for liver cancer: assessing tumor response Expert Rev Anticancer Ther 2017;17(2):119–127 Stulberg JH, Bierman HR Selective hepatic arteriography Normal anatomy, anatomic variations, and pathological conditions Radiology 1965;85:46–55 Tacher V, Radaelli A, Lin M, Geschwind JF How I it: cone-beam CT during transarterial chemoembolization for liver cancer Radiology 2015;274(2):320–334 Takayasu K, Arii S, Ikai I, et al; Liver Cancer Study Group of Japan Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis AJR Am J Roentgenol 2010;194(3):830–837 Tancredi T, McCuskey PA, Kan Z, Wallace S Changes in rat liver microcirculation after experimental hepatic arterial embolization: comparison of different embolic agents Radiology 1999;211(1):177–181 Tang Y, Taylor RR, Gonzalez MV, Lewis AL, Stratford PW Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases J Control Release 2006;116(2):e55–e56 Thomson KR, Cheung W, Ellis SJ, et al Investigation of the safety of irreversible electroporation in humans J Vasc Interv Radiol 2011;22(5):611–621 Varela M, Real MI, Burrel M, et al Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 2007;46(3):474–481 Vouche M, Lewandowski RJ, Atassi R, et al Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection J Hepatol 2013;59(5):1029-1036 Wang YX, De Baere T, Idée JM, Ballet S Transcatheter embolization therapy in liver cancer: an update of clinical evidences Chin J Cancer Res 2015;27(2):96–121 Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization Acta Radiol 2008;49(5):523–529 Yamada R, Nakatsuka H, Nakamura K, et al Hepatic artery embolization in 32 patients with unresectable hepatoma Osaka City Med J 1980;26(2):81–96 Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S Hepatic artery embolization in 120 patients with unresectable hepatoma Radiology 1983;148(2):397–401 Yamagami T, Nakamura T, Iida S, Kato T, Nishimura T Embolization of the right gastric artery before hepatic arterial infusion chemotherapy to prevent gastric mucosal lesions: approach through the hepatic artery versus the left gastric artery AJR Am J Roentgenol 2002;179(6):1605–1610 Yokoyama T, Egami K, Miyamoto M, et al Percutaneous and laparoscopic approaches of radiofrequency ablation treatment for liver cancer J Hepatobiliary Pancreat Surg 2003;10(6):425–427 Yoon CJ, Chung JW, Cho BH, et al., Hepatocellular carcinoma in the caudate lobe of the liver: angiographic analysis of tumor-feeding arteries according to subsegmental location J Vasc Interv Radiol 2008;19(11):1543–1550; quiz 1550 Yu H, Burke CT Comparison of percutaneous ablation technologies in the treatment of malignant liver tumors Semin Intervent Radiol 2014;31(2):129–137 ... BRANT AND HELMS’ FUNDAMENTALS OF DIAGNOSTIC RADIOLOGY FIFTH EDITION ■ EDITORS JEFFREY S KLEIN, MD, FACR A Bradley Soule and John P Tampas Green and Gold Professor of Radiology Department of Radiology. .. Kligerman (Chapter 24 figures 7, 8, 12 15 , 17 and 27; Chapter 25 all figures; Chapter 26 figures 4–7, 9, 10 , 16 ; Chapter 27 figures 7–9, 12 , 13 , 15 , 17 18 , 21 24, 27, 29 and 30; Chapter 28 all figures;... E Brant, MD, FACR Professor Emeritus Department of Radiology and Medical Imaging University of Virginia School of Medicine Charlottesville, Virginia Alan S Brody, MD Professor of Radiology and